In this article, we will discuss Cemiplimab-rwlc (Dosage Overview). So, let’s get started.
Cutaneous Squamous Cell Carcinoma
Cemiplimab-rwlc is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Basal Cell Carcinoma
Cemiplimab-rwlc is indicated for the treatment of patients:
• with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog
pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.
• with metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. The mBCC indication is approved
under accelerated approval based on tumor response rate and durability of response.
Non-Small Cell Lung Cancer
Cemiplimab-rwlc is indicated for the first-line treatment of patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is:
• locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic.
Patient Selection for NSCLC
Select patients with locally advanced or metastatic NSCLC for treatment with Cemiplimab-rwlc based on PD-L1 expression on tumor cells.
The recommended dosage of Cemiplimab-rwlc is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.